BACKGROUND: Inflammation and oxidative stress have been implicated in the pathogenesis of atrial fibrillation (AF). Lipid-lowering drugs, particularly statins and fibrates, possess anti-inflammatory and antioxidant properties. OBJECTIVES: The purpose of this study was to assess the impact of lipid-lowering drug use on AF prevalence in patients with reduced left ventricular ejection fraction (LVEF). METHODS: Data were obtained from ADVANCENT(SM), a multicenter registry of patients with reduced LVEF (<or=40%). Demographic, clinical, and echocardiographic parameters were collected from interviews and medical records. Medications, including lipid-lowering drugs, were recorded. RESULTS: Of the 25,268 patients, 71.3% had hyperlipidemia, and 66.8% were prescribed lipid-lowering drugs. AF prevalence was 25.1% in patients taking lipid-lowering drugs compared with 32.6% in untreated hyperlipidemic patients and 32.8% in patients without hyperlipidemia (P <.001 for both comparisons). In multivariable analysis, lipid-lowering drug use remained significantly associated with reduced odds of AF (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.64-0.74), and this effect was larger than that of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR 0.85, 95% CI 0.79-0.92) or beta-blockers (OR 0.95, 95% CI 0.88-1.02). The beneficial impact of lipid-lowering drugs on AF risk was independent of their effects on the lipid profile. In patients in whom data on specific lipid-lowering drugs were available, 92% of the patients undergoing lipid-lowering therapy received statins, and 98% received statins and/or fibrates. CONCLUSION: Use of lipid-lowering drugs in patients with reduced LVEF is associated with a significant reduction in the prevalence of AF independent of the lipid profile and other known arrhythmia risk factors. This effect is larger than that of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or beta-blockers and may be the result of the antioxidant and anti-inflammatory effects of statins and fibrates.
BACKGROUND: Inflammation and oxidative stress have been implicated in the pathogenesis of atrial fibrillation (AF). Lipid-lowering drugs, particularly statins and fibrates, possess anti-inflammatory and antioxidant properties. OBJECTIVES: The purpose of this study was to assess the impact of lipid-lowering drug use on AF prevalence in patients with reduced left ventricular ejection fraction (LVEF). METHODS: Data were obtained from ADVANCENT(SM), a multicenter registry of patients with reduced LVEF (<or=40%). Demographic, clinical, and echocardiographic parameters were collected from interviews and medical records. Medications, including lipid-lowering drugs, were recorded. RESULTS: Of the 25,268 patients, 71.3% had hyperlipidemia, and 66.8% were prescribed lipid-lowering drugs. AF prevalence was 25.1% in patients taking lipid-lowering drugs compared with 32.6% in untreated hyperlipidemic patients and 32.8% in patients without hyperlipidemia (P <.001 for both comparisons). In multivariable analysis, lipid-lowering drug use remained significantly associated with reduced odds of AF (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.64-0.74), and this effect was larger than that of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (OR 0.85, 95% CI 0.79-0.92) or beta-blockers (OR 0.95, 95% CI 0.88-1.02). The beneficial impact of lipid-lowering drugs on AF risk was independent of their effects on the lipid profile. In patients in whom data on specific lipid-lowering drugs were available, 92% of the patients undergoing lipid-lowering therapy received statins, and 98% received statins and/or fibrates. CONCLUSION: Use of lipid-lowering drugs in patients with reduced LVEF is associated with a significant reduction in the prevalence of AF independent of the lipid profile and other known arrhythmia risk factors. This effect is larger than that of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or beta-blockers and may be the result of the antioxidant and anti-inflammatory effects of statins and fibrates.
Authors: Kriengchai Prasongsukarn; James G Abel; W R Eric Jamieson; Anson Cheung; James A Russell; Keith R Walley; Samuel V Lichtenstein Journal: J Thorac Cardiovasc Surg Date: 2005-07 Impact factor: 5.209
Authors: Koji Fukuda; Sean S Davies; Tadashi Nakajima; Boon-Hooi Ong; Sabina Kupershmidt; Joshua Fessel; Venkataraman Amarnath; Mark E Anderson; Penelope A Boyden; Prakash C Viswanathan; L Jackson Roberts; Jeffrey R Balser Journal: Circ Res Date: 2005-11-10 Impact factor: 17.367
Authors: Kristian Wachtell; Mika Lehto; Eva Gerdts; Michael H Olsen; Björn Hornestam; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Richard B Devereux Journal: J Am Coll Cardiol Date: 2005-03-01 Impact factor: 24.094
Authors: Young M Kim; Tomasz J Guzik; Yin Hua Zhang; Mei Hua Zhang; Hassan Kattach; Chandi Ratnatunga; Ravi Pillai; Keith M Channon; Barbara Casadei Journal: Circ Res Date: 2005-08-25 Impact factor: 17.367
Authors: O Wazni; D O Martin; N F Marrouche; M Shaaraoui; M K Chung; S Almahameed; R A Schweikert; W I Saliba; A Natale Journal: Heart Date: 2005-05-12 Impact factor: 5.994
Authors: Imke Drewitz; Thomas Rostock; Boris Hoffmann; Daniel Steven; Helge Servatius; Thomas Meinertz; Stephan Willems Journal: Med Klin (Munich) Date: 2008-11-15
Authors: Agata Bielecka-Dabrowa; Jan Henryk Goch; Jacek Rysz; Marek Maciejewski; Ravi Desai; Wilbert S Aronow; Maciej Banach Journal: Lipids Health Dis Date: 2010-02-23 Impact factor: 3.876